Solid lipid nanoparticles carrying chemotherapeutic drug across the blood–brain barrier through insulin receptor-mediated pathway

References

• CBTRUS, Statistical report: primary brain tumors in the United States, 1998–2002, Chicago: Central Brain Tumor Registry of the United States (CBTRUS); 2006
   Google Scholar
• Argyriou AA, Antonacopoulou A, Iconomou G, Kalofonos HP. Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009;69:199–210
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood–brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3–14
   PubMedGoogle Scholar
• Pan W, Kastin AJ. Adipokines and the blood–brain barrier. Peptides 2007;28:1317–30
   PubMed Web of Science ®Google Scholar
• See SJ, Gilbert MR. Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol 2004;31:618–34
   PubMed Web of Science ®Google Scholar
• Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Rev 2001;35:161–204
   PubMed Web of Science ®Google Scholar
• Jones AR, Shusta EV. Blood–brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24:1759–71
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–96
   PubMed Web of Science ®Google Scholar
• Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000;210:61–7
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–72
   PubMed Web of Science ®Google Scholar
• Cruz T, Gaspar R, Donato A, Lopes C. Interaction between polyalkylcyanoacrylate nanoparticles and peritoneal macrophages: MTT metabolism, NBT reduction, and NO production. Pharm Res 1997;14:73–9
   PubMed Web of Science ®Google Scholar
• Kawai Y, Takasuka N, Inoue K, et al. Ornithine-containing lipids stimulate CD14-dependent TNF-alpha production from murine macrophage-like J774.1 and RAW 264.7 cells. Fems Immunol Med Mic 2000;28:197–203
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lu CH. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood–brain barrier. Colloids Surf B 2011;86:225–31
   PubMed Web of Science ®Google Scholar
• Shi LJ, Li Z, Yu L, et al. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. J Disper Sci Technol 2011;32:254–9
   Web of Science ®Google Scholar
• Aquilano D, Cavalli R, Gasco MR. Solid lipospheres obtained from hot microemulsions in the presence of different concentrations of cosurfactant: the crystallization of stearic acid polymorphs. Thermochimi Acta 1993;230:29–37
   Web of Science ®Google Scholar
• Boltri L, Canal T, Esposito P. Relevant factors affecting the formation and growth of lipid nanospheres suspensions. Eur J Pharm Biopharm 1995;41:70–5
   Web of Science ®Google Scholar
• Hac-Wydro K, Wydro P. The influence of fatty acids on model cholesterol/phospholipid membranes. Chem Phys Lipids 2007;150:66–81
   PubMed Web of Science ®Google Scholar
• Catelas I, Petit A, Marchand R, et al. Cytotoxicity and macrophage cytokine release induced by ceramic and polyethylene particles in vitro. J Bone Joint Surg 1999;81–B:516–21
   Google Scholar
• Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004;15:897–900
   PubMed Web of Science ®Google Scholar
• Jones CF, Grainger DW. In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev 2009;61:438–56
   PubMed Web of Science ®Google Scholar
• Kim SB, Ozawa T, Tao H, Umezawa Y. A proinflammatory cytokine sensor cell for assaying inflammatory activities of nanoparticles. Anal Biochem 2007;362:148–50
   PubMed Web of Science ®Google Scholar
• Vauthier C, Dubernet C, Fattal E, Patrick C. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003;55:519–48
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54:759–79
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, de Boer AG. Relationship between permeability status of the blood–brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 2000;12:95–102
   PubMed Web of Science ®Google Scholar
• Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood–brain barrier by polybutylcyanoacrylate, methylmethacrylate–sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007;340:143–52
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002;200:629–38
   PubMed Web of Science ®Google Scholar
• Flecher NF, Brayden DJ, Brankin B, et al. Growth and characterisation of a cell culture model of the feline blood-brain barrier. Vet Immunol Immunopathol 2006;109:233–44
   PubMed Web of Science ®Google Scholar
• Kuo YC, Kuo CY. Electromagnetic interference in the permeability of saquinavir across the blood–brain barrier using nanoparticulate carriers. Int J Pharm 2008;351:271–81
   PubMed Web of Science ®Google Scholar
• Alyaudtin R, Reichel A, Lobenberg R, et al. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro. J Drug Target 2001;9:209–21
   PubMed Web of Science ®Google Scholar
• Dehouck B, Fenart L, Dehouck M, et al. A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier. J Cell Biol 1997;138:877–89
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, et al. Apoliporotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J Drug Target 2002;10:317–25
   PubMed Web of Science ®Google Scholar
• Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Congr Ser 2005;1277:85–94
   Google Scholar
• Kuo YC, Chen HH. Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target 2010;18:447–56
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004;25:3065–71
   PubMed Web of Science ®Google Scholar
• Weisgraber KH, Innerarity TL, Harder KJ. The receptor-binding domain of human apolipoprotein E monoclonal antibody inhibition of binding. J Biol Chem 1983;258:12348–54
   PubMedGoogle Scholar